 Home > Active Ingredient News > Antitumor Therapy > Gastric Cancer: Aspirin and long-term survival after gastric adenocarcinoma surgery

Gastric Cancer: Aspirin and long-term survival after gastric adenocarcinoma surgery

 Last Update: 2022-03-05
 Source: Internet
 Author: User

Tags

jp 2 0

carprovet 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Studies have shown that low-dose aspirin use may reduce cancer morbidity and mortality, but its effect on survival in gastric adenocarcinoma is unclear
.

A foreign team conducted a related study to evaluate whether taking aspirin after gastrectomy for gastric adenocarcinoma could improve long-term survival

This population-based cohort study included patients with gastric adenocarcinoma in Sweden who underwent gastrectomy from 2006 to 2015 and were followed up throughout 2020
.

Exposure to daily low-dose (75-160 mg) aspirin 1 year before surgery, 2 years, 3 years, and 1 year after gastrectomy was associated with 5-year all-cause mortality (primary outcome) and disease-specific mortality

Of the 2025 patients included in the study, 545 (26.
9%) used aspirin at the time of surgery
.

Of the patients taking aspirin, 178 (32.

Kaplan–Meier curves showed that there was no statistically significant difference in survival between patients taking and not taking aspirin
.

statistics

Use of aspirin within 1 year before surgery did not reduce the adjusted 5-year risk of all-cause mortality (HR = 0.
98, 95% CI 0.
85-1.
13) or disease-specific mortality (HR = 1.
00, 95% CI 0.
86-1.
17)
.

Taking aspirin within 2 years before surgery (HR = 0.
98, 95% CI 0.
84-1.
15) or within 3 years (HR = 0.
94, 95% CI 0.
79-1.
12) did not reduce the risk of 5-year all-cause mortality
.

Likewise, patients who used aspirin before surgery and 1 year after surgery did not experience any reduction in the risk of all-cause mortality at 5 years (adjusted HR=1.

In the sensitivity analysis, we excluded 291 (14.
3%) patients with gastrectomy without a clear therapeutic purpose
.

In an analysis of 1734 patients, the 90-day mortality rate was 4.

Taken together, studies suggest that low-dose aspirin use may not improve long-term survival after gastric adenocarcinoma surgery

Original source:

Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie SH, Lagergren J.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.